600276 恒瑞医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)7.10314.44114.73910.99110.728
总资产报酬率 ROA (%)6.35012.85113.4939.9889.570
投入资产回报率 ROIC (%)6.81313.96314.57210.64810.332

边际利润分析
销售毛利率 (%)86.32686.20786.24984.55283.612
营业利润率 (%)32.91828.42326.76721.51619.327
息税前利润/营业总收入 (%)31.83326.24423.57418.35616.440
净利润/营业总收入 (%)28.89124.39822.64518.74617.932

收益指标分析
经营活动净收益/利润总额(%)83.64598.03397.30798.68388.905
价值变动净收益/利润总额(%)15.7511.0721.575-2.30211.689
营业外收支净额/利润总额(%)-2.733-3.243-4.476-5.202-3.615

偿债能力分析
流动比率 (X)11.6808.0849.71912.2528.500
速动比率 (X)10.9757.6329.05411.3467.827
资产负债率 (%)8.17211.5518.0696.2849.341
带息债务/全部投入资本 (%)0.8112.428-0.0540.9724.048
股东权益/带息债务 (%)11,951.0943,910.016-184,059.23510,140.5082,350.520
股东权益/负债合计 (%)1,114.684759.2111,125.2271,470.724955.631
利息保障倍数 (X)-151.891-20.398-11.518-8.756-7.428

营运能力分析
应收账款周转天数 (天)58.62157.25965.02587.44489.038
存货周转天数 (天)250.085218.490221.301243.282250.552